Untitled Document

Assay for SHIP1 expression as a Predictor of Inflammatory Bowel Disease Risk

Licensing Status: Available for Licensing

Find a summary of this technology here

Current Problem: Identifying patients who are more susceptible to inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.

Upstate's Solution:

The research group of Dr. Bill Kerr has discovered that the underexpression of the SHIP1 (INPP5D) gene in the peripheral blood mononuclear cells is indicative of a colon disorder. This can especially be seen by comparing subjects in experiment 2 in the chart below, P5-P8 for Crohn's patients and C3-C5 for healthy controls. SHIP1 activity is less in the Crohn's patients than in the healthy controls.

Dr. Kerr's group has also identified a number of SNP's at different locations on INPP5D (SHIP1) that were determined to be indicative of colon disorders. Since the paper on this aspect of SHIP has not yet published, information on the SNPs is redacted. Based on a large set from the SNP database in the University of California Santa Cruz (UCSC) Genome Browser on Human Feb. 2009 (GRCh37/hg19), an expected frequency was determined, a determination was made as to the frequency of the SNP in a number of individuals. For example, in evaluating the first SNP in the table, the INPP5D gene of the 29 subjects was sequenced. It was determined that 38% of the tested subjects with the specific SNP had Crohn's disease, 30% of the tested subjects with the specific SNP had ulcerative colitis and 25% of the tested subjects with the specific SNP did not have any colon disorders.

Link to Dr. Kerr's Faculty Profile Page